ASX:MSBBiotechs
Mesoblast (ASX:MSB) Is Down 17.9% After Revenue Surge Accompanied by Deeper Net Losses – Has the Bull Case Changed?
Mesoblast Limited recently reported its full-year earnings for the period ended June 30, 2025, showing revenue of US$17.2 million compared to US$5.9 million the previous year and a net loss of US$102.14 million.
A notable insight is that while revenue increased very significantly, the company’s net loss also widened year-over-year, reflecting both commercial progress and ongoing operating challenges.
We'll explore how the sharp rise in revenue alongside continued net losses could shift...